You do not automatically have to stop a GLP-1 before a colonoscopy — but you do have to tell your endoscopy team you take one, and your bowel prep deserves more care than the average patient’s. Here is what the current clinical guidance actually says.
Why GLP-1s and colonoscopies keep crossing paths
Two demographic curves are intersecting. Colorectal cancer screening now begins at age 45 for average-risk adults, after the U.S. Preventive Services Task Force lowered the starting age from 50 in 2021 [5]. At the same time, GLP-1 medications — including semaglutide and tirzepatide — have become some of the most widely prescribed therapies in the country, heavily concentrated in the exact 40-to-60 age band now due for first or repeat colonoscopies.
That means millions of people will schedule a screening colonoscopy while taking a medication that deliberately slows gastric emptying. Slowed stomach emptying is not a side effect of GLP-1 therapy; it is part of how the medication works. It is also the single property that anesthesia and endoscopy teams care about most, because sedating a patient with food still in the stomach raises the risk of aspiration.
A colonoscopy by itself is a lower-stakes scenario than surgery under general anesthesia — the procedure examines the colon, the prep empties the bowel, and the day-before diet is already liquid. But sedation is still sedation, prep quality still determines whether the exam finds what it needs to find, and the protocols changed meaningfully between 2023 and 2024. If you read our guide to GLP-1s before surgery, this is the colonoscopy-specific chapter.
Do you need to stop your GLP-1 before a colonoscopy?
The honest answer: it depends on your symptoms, your procedure, and your endoscopy center’s protocol — and the trend in the guidance has moved away from automatic holds.
In 2023, the American Society of Anesthesiologists issued the first consensus guidance, recommending that patients hold daily GLP-1 formulations the day of a procedure and weekly formulations for a full week beforehand, out of caution about retained gastric contents [2]. Gastroenterologists pushed back almost immediately. The American Gastroenterological Association’s Rapid Clinical Practice Update advised that patients without symptoms of delayed stomach emptying — nausea, vomiting, early fullness, significant bloating — generally do not need procedures postponed, and that standard fasting plus a clear-liquid day is sufficient for most [3].
The 2024 multi-society clinical practice guidance — issued jointly by the anesthesiology, gastroenterology, bariatric surgery, and perioperative care societies — is now the reference document, and it replaced blanket rules with shared decision-making [1]. Its core logic:
- Most patients without elevated risk can continue their GLP-1 medication through the procedure window, paired with a 24-hour clear-liquid diet beforehand.
- Patients with elevated risk of delayed gastric emptying — active GI symptoms, recent dose escalation, or conditions like gastroparesis — warrant individualized planning, which may include holding a dose.
- The decision is made jointly by the procedural team, the anesthesia team, and the prescribing physician — balancing aspiration safety against the metabolic reasons the medication was prescribed.
For a standard screening colonoscopy, this guidance lands in a convenient place: the prep itself already requires a clear-liquid diet the day before. In many cases, the colonoscopy prep and the GLP-1 precaution are the same instruction.
The bowel prep question — what the research actually shows
Aspiration gets the headlines, but for a colonoscopy specifically, the more practical question is prep quality. A colonoscopy is only as good as the view, and an inadequate prep can mean missed polyps or a repeat procedure.
Here the evidence is genuinely mixed. The largest cohort to date — 6,235 patients across 22 endoscopy units in a U.S. health system — found that patients actively taking a GLP-1 had significantly lower Boston Bowel Preparation Scale scores and were more likely to have an inadequate prep, even after controlling for diabetes, BMI, and other variables [4]. A 2025 systematic review and meta-analysis pooling roughly 11,000 patients, by contrast, found no significant overall effect and did not recommend stopping GLP-1s for prep reasons alone. Some of the discrepancy likely reflects diabetes itself, which independently slows GI motility.
You do not need to adjudicate that debate. You need to prep like someone who might be slower to clear:
- Start the runway early. Shift toward a low-residue diet — lower fiber, no seeds, skins, nuts, or raw vegetables — two to three days before the procedure instead of one.
- Take the clear-liquid day seriously. The full day before, not a half-hearted afternoon version. Clear broth, water, electrolyte drinks, plain gelatin — nothing red or purple.
- Complete the entire split-dose prep. The second dose, timed the morning of the procedure per your instructions, is the one patients most often shortchange — and the one that matters most for the right side of the colon.
- Hydrate beyond the prep itself. GLP-1s blunt thirst cues for many people. Set a fluid target rather than waiting to feel thirsty.
- Report a failed prep honestly. If your output never ran clear, tell the endoscopy team before sedation — rescheduling beats an exam that cannot visualize the colon.
What to tell your endoscopy team — and when
Every protocol above depends on one thing happening: the endoscopy center knowing you take a GLP-1 before the day of the procedure. Disclose at scheduling, not at check-in. Specifically:
- The name of the active ingredient and your current dose
- Whether it is a daily or weekly formulation, and the date of your last dose
- How long you have been at your current dose (recent escalations matter)
- Any GI symptoms — nausea, vomiting, early fullness, reflux, constipation
- Whether an upper endoscopy is being done at the same time
That last item deserves emphasis. A combined upper endoscopy and colonoscopy changes the calculus, because the upper exam is exactly where retained stomach contents become both a visibility problem and an aspiration risk. Centers commonly apply stricter fasting or medication-hold rules to combined procedures — let them apply theirs.
If you are an Elara Health & Wellness patient, loop in your prescribing physician as soon as the colonoscopy is scheduled. Coordinating a hold (if one is needed) and the restart afterward is routine — the same coordination we describe in our guide to lab work and monitoring on GLP-1 therapy.
After the procedure: restarting without drama
For a routine screening colonoscopy where the medication was continued, there is nothing to restart — resume normal eating as your sedation wears off and take your next dose on schedule. If a dose was held, the restart is usually simple: once you are eating and drinking normally and any lingering nausea has passed, most prescribing physicians resume at the same dose. A single missed weekly dose around a procedure does not typically require re-titration from a lower dose.
One practical note: the day after a colonoscopy is a gentle-eating day for everyone, GLP-1 or not. Smaller portions, simple foods, and steady fluids will feel better and align with how most patients on GLP-1 therapy already eat.
A final framing
It would be easy to read the last two years of shifting guidance and conclude that being on a GLP-1 makes a colonoscopy complicated. The opposite conclusion is more accurate: the medical community studied the question quickly, and the answer that emerged is manageable — disclose early, prep diligently, follow your center’s protocol, and coordinate any hold with your prescribing physician [1].
What would actually be complicated is a colorectal cancer found late because a screening was postponed. Screening starting at 45 exists because it works [5]. Your GLP-1 is a logistics detail. Your colonoscopy is not.
Frequently asked questions
Do I have to stop my GLP-1 medication before a colonoscopy?
Not necessarily. The 2024 multi-society clinical practice guidance moved away from blanket hold instructions toward individualized, shared decision-making. Many patients without symptoms of delayed stomach emptying can continue their medication and follow a clear-liquid diet the day before the procedure — which a standard colonoscopy prep already requires. The decision belongs to your endoscopy team and your prescribing physician, not to a blog post. Ask both, early.
Will my GLP-1 affect my bowel prep?
The research is mixed. One large multicenter cohort of more than 6,000 patients found that GLP-1 users had lower bowel-prep quality scores and more inadequate preps, while a 2025 meta-analysis found no significant overall effect. The practical takeaway is the same either way: follow your prep instructions exactly, favor a low-residue diet in the days beforehand, hydrate aggressively, and complete the full split-dose prep.
What if I’m having an upper endoscopy at the same time as my colonoscopy?
Combined procedures raise the stakes, because upper endoscopy is where retained stomach contents matter most. Slowed gastric emptying is the core reason anesthesia teams care about GLP-1s. Tell the scheduling team about your medication when the combined procedure is booked so they can apply their protocol — which may include a longer clear-liquid window or a medication hold.
Does it matter that my GLP-1 is compounded?
The perioperative considerations relate to the pharmacologic mechanism — delayed gastric emptying — not to how the prescription was filled. Disclose the active ingredient, the strength, and the date of your most recent dose, and let the endoscopy team apply the same protocol they would for any GLP-1 medication.
When can I restart my GLP-1 after the colonoscopy?
If your medication was held, most prescribing physicians restart once you are eating and drinking normally and any post-sedation nausea has resolved — often within a day or two for a routine screening colonoscopy. For weekly formulations, missing a single dose around the procedure window generally does not require re-titration. Confirm the restart plan with your prescribing physician.
Should I delay my colonoscopy because I’m on a GLP-1?
No — and this matters. Colorectal cancer screening is recommended for all average-risk adults starting at age 45, and screening is one of the most effective cancer-prevention tools in medicine. Being on a GLP-1 is a planning detail to manage, not a reason to postpone screening. Coordinate; don’t cancel.
References
- Multi-society clinical practice guidance for the safe use of glucagon-like peptide-1 receptor agonists in the perioperative period. American Gastroenterological Association, American Society of Anesthesiologists, American Society for Metabolic and Bariatric Surgery, International Society of Perioperative Care of Patients with Obesity, and SAGES. 2024. Full text via PubMed Central
- American Society of Anesthesiologists. Consensus-based guidance on preoperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. 2023, updated 2024. ASA guidance statement
- Hashash JG, Thompson CC, Wang AY. AGA Rapid Clinical Practice Update on the Management of Patients Taking GLP-1 Receptor Agonists Prior to Endoscopy: Communication. Clinical Gastroenterology and Hepatology. 2024;22(4):705–707. Journal article
- Quality of bowel preparation for colonoscopy in patients on glucagon-like peptide-1 receptor agonists: a multicenter cohort of 6,235 patients. Gastrointestinal Endoscopy. 2024. Journal abstract
- U.S. Preventive Services Task Force. Screening for Colorectal Cancer: Final Recommendation Statement. JAMA. 2021. USPSTF recommendation
This article is for educational purposes only and is not medical advice. It does not replace the individualized guidance of your gastroenterologist, anesthesia team, or prescribing physician. Always follow the specific prep and medication instructions provided by your endoscopy center.